Compare VYGR & BKKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | BKKT |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.4M | 241.3M |
| IPO Year | 2015 | N/A |
| Metric | VYGR | BKKT |
|---|---|---|
| Price | $3.89 | $13.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $17.00 | $13.00 |
| AVG Volume (30 Days) | 667.5K | ★ 1.9M |
| Earning Date | 03-10-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $31,316,000.00 | ★ $3,871,476,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $71.78 | $2.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 107.11 |
| 52 Week Low | $2.65 | $6.81 |
| 52 Week High | $5.78 | $49.79 |
| Indicator | VYGR | BKKT |
|---|---|---|
| Relative Strength Index (RSI) | 45.43 | 43.53 |
| Support Level | $3.86 | $13.69 |
| Resistance Level | $4.11 | $15.61 |
| Average True Range (ATR) | 0.25 | 2.23 |
| MACD | 0.01 | -0.47 |
| Stochastic Oscillator | 47.79 | 3.82 |
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Bakkt Holdings Inc operates technology that connects the digital economy by offering a platform for crypto and redeeming loyalty points. Its institutional-grade technology platform provides a custody solution that caters to more experienced market participants to store crypto and provides consumers, businesses, and institutions with the ability to buy, sell, and store crypto in a simple, intuitive digital experience accessed via application programming interfaces (APIs) or embedded web experience and Loyalty offers a full spectrum of content that clients can make available to its customers when redeeming loyalty currencies. It generates revenue in the form of Subscription and service and Transaction revenue.